Evaluation of prescribing pattern of drugs and compliance to standard treatment guidelines in patients of chronic hepatitis B: a prospective observational study
Keywords:Chronic hepatitis B, Prescribing pattern, Antiviral drugs, Compliance to guidelines
Background: Hepatitis B is a major global health problem. Chronic hepatitis B is characterized by hepatic inflammation, necrosis and persistence of HbsAg for at least 6 months. Chronic liver disease is more predictably associated with impaired metabolism of drugs than acute liver dysfunction. Prescribing drugs in patients with chronic hepatitis B is challenging because of concerns that the drug may exacerbate the liver disease. There is also the fear that the altered liver state may change metabolism and excretion of the drug.
Methods: A cross-sectional prospective study was conducted involving patients diagnosed with chronic hepatitis B at the liver clinic outpatient department (OPD) of AIIMS Bhopal. A total of 102 patients with chronic hepatitis B who met the inclusion criteria were recruited in the study.
Results: Out of 102 prescriptions, 492 drugs were prescribed for the 102 patients. Out of 102 patients, 81 patients (81.66%) were on entecavir monotherapy and rest 21 patients (18.34%) were on tenofovir disoproxil fumarate (TDF) monotherapy. Of the 102-prescription issued, 92.15% (94/102) were compliant and 7.85% (8/102) were noncompliant.
Conclusions: Entecavir was the most common antiviral drug prescribed, followed by tenofovir in patients of chronic hepatitis B. Spironolactone plus torasemide combination was the most common fixed dose combination used among study participants. Liver cirrhosis followed by portal hypertension was the most common complication. Majority of prescriptions were compliant with recommendations for pharmacotherapy and safety guidelines in patients of chronic hepatitis B.
Jules L. Dienstag. Harrisons Principal of Internal Medicine. 20th edition. Mac Graw Hill Education; Chapter 334. Chronic Hepatitis. 2020;2375-89.
World Health Organization (WHO) Global Hepatitis Report. World Health Organization; Geneva, Switzerland. 2017. Available at: https://www.who. int/publications/i /item/9789241565455. Accessed on 3 March 2023.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-55.
Ganem D, Prince AM. Hepatitis B virus infection-Natural history and clinical consequences. N Engl J Med. 2004;350:1118-9.
Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: Summary of a clinical research workshop. Hepatology. 2007;45:1056-75.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99.
Angeli P, Bernardi M, Villanueva C. “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60.
Amarapurkar DN. Prescribing medications in patients with decompensated liver cirrhosis. Int J Hepatol. 2011;5:2011.
Pirmohamed M. Liver feature. Afr J Respiratory Med. 2016;17-25.
Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529-45.
Weersink RA, Taxis K, Drenth JPH, Houben E, Metselaar HJ, Borgsteede SD. Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real-world study. Drug Safety. 2019;42(4):539-46.
Mohammed BS, Aidoo M. Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines? Int J Hepatol. 2020;;2020:9750194
Yun Bin L. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrobial Agents Chemotherapy. 2014;58(11):6710-16.
Green TE, Bandy SM. Spontaneous bacterial peritonitis. 2018.
Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. American Association for the Study of Liver Disease. 2012.
Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-3.
Clinical Practice Guidelines. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417.
Committee JF, British National Formulary, Royal Pharmaceutical Society Publishing. 2018.
Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, 2002. Ann Internal Med. 2017;137(12):947-54.
Medscape, Medscape Drug Monograph, 2019.
Megan W. Pain management considerations in cirrhosis, 2015. Available at: https://www.uspharmacist.com/article/pain-managment-considerations-in-cirrhosis. Accessed on 25 March, 2023.
Robles-Diaz M, Lucena MI, Kaplowitz N. DILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109-18.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM et al. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84(8):1806-20.
Hayward KL, Patel PJ, Valery PC. Medication related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention. Hepatol Communications. 2019;3(5):620-31.